Wekerle H. Nature, nurture, and microbes: the development of multiple sclerosis. Acta Neurol Scand. 2017;136(Suppl 201):22–5.
Google Scholar
Mische LJ, Mowry EM. The evidence for dietary interventions and nutritional supplements as treatment options in multiple sclerosis: a review. Curr Treat Options Neurol. 2018;20(4):8.
Google Scholar
Mousavi-Shirazi-Fard Z, Mazloom Z, Izadi S, Fararouei M. The effects of modified anti-inflammatory diet on fatigue, quality of life, and inflammatory biomarkers in relapsing-remitting multiple sclerosis patients: a randomized clinical trial. Int J Neurosci. 2021;131(7):657–65.
Google Scholar
Yadav V, Marracci G, Kim E, Spain R, Cameron M, Overs S, Riddehough A, Li DK, McDougall J, Lovera J, Murchison C, Bourdette D. Low-fat, plant-based diet in multiple sclerosis: A randomized controlled trial. Mult Scler Relat Disord. 2016;9:80–90.
Google Scholar
Storoni M, Plant GT. The therapeutic potential of the ketogenic diet in treating progressive multiple sclerosis. Mult Scler Int. 2015;2015:681289.
Google Scholar
Piccio L, Stark JL, Cross AH. Chronic calorie restriction attenuates experimental autoimmune encephalomyelitis. J Leukoc Biol. 2008;84(4):940–8.
Google Scholar
Kafami L, Raza M, Razavi A, Mirshafiey A, Movahedian M, Khorramizadeh MR. Intermittent feeding attenuates clinical course of experimental autoimmune encephalomyelitis in C57BL/6 mice. Avicenna J Med Biotechnol. 2010;2(1):47–52.
Google Scholar
Razeghi Jahromi S, Ghaemi A, Alizadeh A, Sabetghadam F, Moradi Tabriz H, Togha M. Effects of intermittent fasting on experimental autoimune encephalomyelitis in C57BL/6 mice. Iran J Allergy Asthma Immunol. 2016;15(3):212–9.
Google Scholar
Fitzgerald KC, Vizthum D, Henry-Barron B, Schweitzer A, Cassard SD, Kossoff E, Hartman AL, Kapogiannis D, Sullivan P, Baer DJ, Mattson MP, Appel LJ, Mowry EM. Effect of intermittent vs. daily calorie restriction on changes in weight and patient-reported outcomes in people with multiple sclerosis. Mult Scler Relat Disord. 2018;23:33–9.
Google Scholar
Winesett SP, Bessone SK, Kossoff EH. The ketogenic diet in pharmacoresistant childhood epilepsy. Expert Rev Neurother. 2015;15(6):621–8.
Google Scholar
Kossoff EH. More fat and fewer seizures: dietary therapies for epilepsy. Lancet Neurol. 2004;3(7):415–20.
Google Scholar
Reger MA, Henderson ST, Hale C, Cholerton B, Baker LD, Watson GS, Hyde K, Chapman D, Craft S. Effects of beta-hydroxybutyrate on cognition in memory-impaired adults. Neurobiol Aging. 2004;25(3):311–4.
Google Scholar
Vanitallie TB, Nonas C, Di Rocco A, Boyar K, Hyams K, Heymsfield SB. Treatment of Parkinson disease with diet-induced hyperketonemia: a feasibility study. Neurology. 2005;64(4):728–30.
Google Scholar
Kim DY, Hao J, Liu R, Turner G, Shi FD, Rho JM. Inflammation-mediated memory dysfunction and effects of a ketogenic diet in a murine model of multiple sclerosis. PLoS ONE. 2012;7(5):e35476.
Google Scholar
Choi IY, Piccio L, Childress P, Bollman B, Ghosh A, Brandhorst S, Suarez J, Michalsen A, Cross AH, Morgan TE, Wei M, Paul F, Bock M, Longo VD. A diet mimicking fasting promotes regeneration and reduces autoimmunity and multiple sclerosis symptoms. Cell Rep. 2016;15(10):2136–46.
Google Scholar
Brenton JN, Banwell B, Bergqvist AGC, Lehner-Gulotta D, Gampper L, Leytham E, Coleman R, Goldman MD. Pilot study of a ketogenic diet in relapsing-remitting MS. Neurol Neuroimmunol Neuroinflamm. 2019;6(4):e565.
Google Scholar
Brenton JN, Lehner-Gulotta D, Woolbright E, Banwell B, Bergqvist AGC, Chen S, Coleman R, Conaway M, Goldman MD. Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits. J Neurol Neurosurg Psychiatry. 2022;93(6):637–44.
Google Scholar
Bahr LS, Bock M, Liebscher D, Bellmann-Strobl J, Franz L, Pruss A, Schumann D, Piper SK, Kessler CS, Steckhan N, Michalsen A, Paul F, Mahler A. Ketogenic diet and fasting diet as nutritional approaches in multiple sclerosis (NAMS): protocol of a randomized controlled study. Trials. 2020;21(1):3.
Google Scholar
Bahr LS. Effects of fasting and a ketogenic diet on neuropsychiatric outcomes in multiple sclerosis patients – a randomized controlled trial. Charié – Universitätsmedizin Berlin 2022.
Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, Correale J, Fazekas F, Filippi M, Freedman MS, Fujihara K, Galetta SL, Hartung HP, Kappos L, Lublin FD, Marrie RA, Miller AE, Miller DH, Montalban X, Mowry EM, Sorensen PS, Tintore M, Traboulsee AL, Trojano M, Uitdehaag BMJ, Vukusic S, Waubant E, Weinshenker BG, Reingold SC, Cohen JA. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162–73.
Google Scholar
Wilhelmi de Toledo F, Buchinger A, Burggrabe H, Holz G, Kuhn C, Lischka E, Lischka N, Lutzner H, May W, Ritzmann-Widderich M, Stange R, Wessel A, Boschmann M, Peper E, Michalsen A. Medical association for F, nutrition. Fasting therapy – an expert panel update of the 2002 consensus guidelines. Forsch Komplementmed. 2013;20(6):434–43.
Google Scholar
Hamilton GF, McDonald C, Chenier TC. Measurement of grip strength: validity and reliability of the sphygmomanometer and Jamar grip dynamometer. J Orthop Sports Phys Ther. 1992;16(5):215–9.
Google Scholar
Goldman MD, Marrie RA, Cohen JA. Evaluation of the six-minute walk in multiple sclerosis subjects and healthy controls. Mult Scler. 2008;14(3):383–90.
Google Scholar
Fischer JS, Rudick RA, Cutter GR, Reingold SC. The multiple sclerosis functional composite measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS society clinical outcomes assessment task force. Mult Scler. 1999;5(4):244–50.
Google Scholar
Smith A. Symbol digit modalities test (Revised). Western Psychological Services. 1982.
Aaron T, Beck RAS, Gregory K. Brown. Beck Depression Inventory – 2nd Edition (BDI-II)1996.
Wintjen L, Petermann F. Beck-Depressions-Inventar revision (BDI-II). Z Psychiatr Psych Ps. 2010;58(3):243–5.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121–3.
Google Scholar
Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW. A health-related quality of life measure for multiple sclerosis. Qual Life Res. 1995;4(3):187–206.
Google Scholar
Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O’Neal L, McLeod L, Delacqua G, Delacqua F, Kirby J, Duda SN, Consortium RE. The REDCap consortium: Building an international community of software platform partners. J Biomed Inf. 2019;95:103208.
Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inf. 2009;42(2):377–81.
R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2023 [Available from: https://www.R-project.org/
Saul AM, Taylor BV, Blizzard L, Simpson-Yap S, Oddy WH, Shivappa N, Hébert JR, Black LJ, Ponsonby AL, Broadley SA, Lechner-Scott J, van der Mei I, Investigators AA. A pro-inflammatory diet in people with multiple sclerosis is associated with an increased rate of relapse and increased FLAIR lesion volume on MRI in early multiple sclerosis: A prospective cohort study. Mult Scler J. 2023;29(8):1012–23.
Google Scholar
Rahmani F, Ghezzi L, Tosti V, Liu J, Song SK, Wu AT, Rajamanickam J, Obert KA, Benzinger TLS, Mittendorfer B, Piccio L, Raji CA. Twelve weeks of intermittent caloric restriction diet mitigates neuroinflammation in midlife individuals with multiple sclerosis: A pilot study with implications for prevention of alzheimer’s disease. J Alzheimers Dis. 2023;93(1):263–73.
Google Scholar
Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, Tornatore C, Sweetser MT, Yang M, Sheikh SI, Dawson KT, Investigators DS. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.
Google Scholar
Kuhle J, Plavina T, Barro C, Disanto G, Sangurdekar D, Singh CM, de Moor C, Engle B, Kieseier BC, Fisher E, Kappos L, Rudick RA, Goyal J. Neurofilament light levels are associated with long-term outcomes in multiple sclerosis. Mult Scler. 2020;26(13):1691–9.
Google Scholar
Harris S, Comi G, Cree BAC, Arnold DL, Steinman L, Sheffield JK, Southworth H, Kappos L, Cohen JA, Investigators OS. Plasma neurofilament light chain concentrations as a biomarker of clinical and radiologic outcomes in relapsing multiple sclerosis: post hoc analysis of phase 3 ozanimod trials. Eur J Neurol. 2021;28(11):3722–30.
Google Scholar
Kuhle J, Kropshofer H, Haering DA, Kundu U, Meinert R, Barro C, Dahlke F, Tomic D, Leppert D, Kappos L. Blood neurofilament light chain as a biomarker of MS disease activity and treatment response. Neurology. 2019;92(10):E1007–15.
Google Scholar
Oh U, Woolbright E, Lehner-Gulotta D, Coleman R, Conaway M, Goldman MD, Brenton JN. Serum neurofilament light chain in relapsing multiple sclerosis patients on a ketogenic diet. Mult Scler Relat Disord. 2023;73:104670.
Google Scholar
Silveira C, Guedes R, Maia D, Curral R, Coelho R. Neuropsychiatric symptoms of multiple sclerosis: state of the Art. Psychiatry Investig. 2019;16(12):877–88.
Google Scholar
Lee JE, Titcomb TJ, Bisht B, Rubenstein LM, Louison R, Wahls TL. A modified MCT-Based ketogenic diet increases plasma beta-Hydroxybutyrate but has less effect on fatigue and quality of life in people with multiple sclerosis compared to a modified paleolithic diet: A Waitlist-Controlled, randomized pilot study. J Am Coll Nutr. 2020;40:1–13.
Benedict RH, Cohan S, Lynch SG, Riester K, Wang P, Castro-Borrero W, Elkins J, Sabatella G. Improved cognitive outcomes in patients with relapsing-remitting multiple sclerosis treated with daclizumab beta: results from the DECIDE study. Mult Scler. 2018;24(6):795–804.
Google Scholar
Button KS, Kounali D, Thomas L, Wiles NJ, Peters TJ, Welton NJ, Ades AE, Lewis G. Minimal clinically important difference on the Beck depression Inventory–II according to the patient’s perspective. Psychol Med. 2015;45(15):3269–79.
Google Scholar
Fond G, Macgregor A, Leboyer M, Michalsen A. Fasting in mood disorders: neurobiology and effectiveness. A review of the literature. Psychiatry Res. 2013;209(3):253–8.
Google Scholar
Gibson AA, Seimon RV, Lee CM, Ayre J, Franklin J, Markovic TP, Caterson ID, Sainsbury A. Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. Obes Rev. 2015;16(1):64–76.
Google Scholar
Michalsen A, Schlegel F, Rodenbeck A, Ludtke R, Huether G, Teschler H, Dobos GJ. Effects of short-term modified fasting on sleep patterns and daytime vigilance in non-obese subjects: results of a pilot study. Ann Nutr Metab. 2003;47(5):194–200.
Google Scholar
Górska E, Tylicka M, Hermanowicz A, Matuszczak E, Sankiewicz A, Gorodkiewicz E, Hermanowicz J, Karpinska E, Socha K, Kochanowicz J, Jakoniuk M, Kaminska J, Homsak E, Koper-Lenkiewicz OM. UCHL1, besides leptin and fibronectin, also could be a sensitive marker of the relapsing-remitting type of multiple sclerosis. Sci Rep-Uk. 2023;13(1).
Moharami S, Nourazarian A, Nikanfar M, Laghousi D, Shademan B, Joodi Khanghah O, Khaki-Khatibi F. Investigation of serum levels of orexin-A, transforming growth factor beta, and leptin in patients with multiple sclerosis. J Clin Lab Anal. 2022;36(1):e24170.
Google Scholar
Matarese G, Carrieri PB, La Cava A, Perna F, Sanna V, De Rosa V, Aufiero D, Fontana S, Zappacosta S. Leptin increase in multiple sclerosis associates with reduced number of CD4(+)CD25 + regulatory T cells. Proc Natl Acad Sci U S A. 2005;102(14):5150–5.
Google Scholar
Loonstra FC, Falize KF, de Ruiter LRJ, Schoonheim MM, Strijbis EMM, Killestein J, de Vries HE, Uitdehaag BMJ, Rijnsburger M. Adipokines in multiple sclerosis patients are related to clinical and radiological measures. J Neurol. 2023;270(4):2018–30.
Google Scholar
Igwe O, Sone M, Matveychuk D, Baker GB, Dursun SM. A review of effects of calorie restriction and fasting with potential relevance to depression. Prog Neuropsychopharmacol Biol Psychiatry. 2021;111:110206.
Google Scholar
Siddiqui K, Browne RW, Benedict RHB, Jakimovski D, Weinstock-Guttman B, Zivadinov R, Ramanathan M. Cholesterol pathway biomarkers are associated with neuropsychological measures in multiple sclerosis. Mult Scler Relat Disord. 2023;69:104374.
Google Scholar
Andaloro A, Russo M, Pastura C, Sessa E, Calatozzo P, Maggio MG, Bramanti P. Is there a correlation between dyslipidemia and cognitive impairment in patients with multiple sclerosis? Int J Neurosci. 2020;132.
Noori H, Gheini MR, Rezaeimanesh N, Saeedi R, Aliabadi HR, Sahraian MA, Moghadasi AN. The correlation between dyslipidemia and cognitive impairment in multiple sclerosis patients. Mult Scler Relat Dis. 2019;36.
Hernandez-Ledesma AL, Rodriguez-Mendez AJ, Gallardo-Vidal LS, Garcia-Gasca T, Alatorre-Cruz JM, Garcia-Solis P, Lopez Reyes J, Solis-Sainz JC. Lipid profile: causal relationship on cognitive performance in multiple sclerosis? Mol Biol Rep. 2020;47(12):9667–76.
Google Scholar
Silva AS, Guimaraes J, Sousa C, Mendonca L, Soares-Dos-Reis R, Mendonca T, Abreu P, Sequeira L, Sa MJ. Metabolic syndrome parameters and multiple sclerosis disease outcomes: A Portuguese cross-sectional study. Mult Scler Relat Disord. 2023;69:104370.
Google Scholar
Oliveira SR, Simao AN, Kallaur AP, de Almeida ER, Morimoto HK, Lopes J, Dichi I, Kaimen-Maciel DR, Reiche EM. Disability in patients with multiple sclerosis: influence of insulin resistance, adiposity, and oxidative stress. Nutrition. 2014;30(3):268–73.
Google Scholar
Penesova A, Vlcek M, Imrich R, Vernerova L, Marko A, Meskova M, Grunnerova L, Turcani P, Jezova D, Kollar B. Hyperinsulinemia in newly diagnosed patients with multiple sclerosis. Metab Brain Dis. 2015;30(4):895–901.
Google Scholar
Zhornitsky S, McKay KA, Metz LM, Teunissen CE, Rangachari M. Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. Mult Scler Relat Disord. 2016;5:53–65.
Google Scholar
Dossi DE, Chaves H, Heck ES, Rodriguez Murua S, Ventrice F, Bakshi R, Quintana FJ, Correale J, Farez MF. Effects of systolic blood pressure on brain integrity in multiple sclerosis. Front Neurol. 2018;9:487.
Google Scholar
Motl RW, Baird JF, Sandroff BM, Baynard T, Fernhall B. Blood pressure and cognition in older adults with multiple sclerosis: preliminary examination. Neurol Sci. 2023;44(2):677–83.
Google Scholar
Marrie RA, Patel R, Figley CR, Kornelsen J, Bolton JM, Graff LA, Mazerolle EL, Helmick C, Uddin MN, Figley TD, Marriott JJ, Bernstein CN, Fisk JD. Effects of vascular comorbidity on cognition in multiple sclerosis are partially mediated by changes in brain structure. Front Neurol. 2022;13:910014.
Google Scholar
Roman SN, Fitzgerald KC, Beier M, Mowry EM. Safety and feasibility of various fasting -mimicking diets among people with multiple sclerosis. Mult Scler Relat Dis. 2020;42.